Welcome to our dedicated page for Merck & Co news (Ticker: MRK), a resource for investors and traders seeking the latest updates and insights on Merck & Co stock.
Merck & Co., Inc. (NYSE: MRK), known as MSD outside the United States and Canada, generates frequent news across human health, animal health and corporate finance. As a research-intensive biopharmaceutical company with more than a century of history developing medicines and vaccines, Merck regularly announces clinical trial milestones, regulatory decisions, business development transactions and capital markets activity.
Recent news highlights include oncology updates from Merck’s extensive KEYTRUDA program, such as positive Phase 3 data in muscle-invasive bladder cancer and new trials in non-small cell lung cancer using combinations like calderasib (MK-1084) with KEYTRUDA QLEX. The company also reports on progress in other therapeutic areas, including pulmonary arterial hypertension with WINREVAIR, Alzheimer’s disease candidates MK-2214 and MK-1167, and cardiovascular research with the oral PCSK9 inhibitor candidate enlicitide.
Investors following MRK news will also see announcements related to Merck Animal Health, such as the conditional U.S. FDA approval of EXZOLT CATTLE-CA1 for the prevention and treatment of New World screwworm larvae and the treatment and control of cattle fever tick, as well as updates on acquisitions like the planned merger with Cidara Therapeutics to add the influenza candidate CD388 to Merck’s respiratory portfolio.
Corporate and financial communications include quarterly earnings calls, participation in major healthcare conferences and disclosures about note offerings under the company’s shelf registration statement. This news page aggregates these developments so readers can review clinical, regulatory, strategic and financial updates related to Merck & Co., Inc. and its MRK stock in one place.
Merck (NYSE: MRK) will present first-in-human data for two Alzheimer’s candidates, MK-2214 and MK-1167, at CTAD 2025 in San Diego, Dec 1–4, 2025.
MK-2214 is a novel antibody targeting phosphorylated serine 413 (pS413) tau; Merck reported Phase 1 safety, tolerability and pharmacokinetics from three studies and said those results informed an ongoing Phase 2 trial (NCT07033494). The U.S. FDA granted Fast Track designation to MK-2214 for Alzheimer’s disease.
MK-1167 is an oral positive allosteric modulator of the α7 nicotinic receptor; Merck presented Phase 1 proof-of-biology data on glutamate metabolism that informed Phase 2 dose selection (NCT06721156).
Merck (NYSE: MRK) said Chirfi Guindo, chief marketing officer, Human Health, and Dr. Eliav Barr, senior vice president and chief medical officer, Merck Research Laboratories, will take part in a fireside chat at the Citi 2025 Global Healthcare Conference on Wednesday, Dec. 3, 2025 at 1:00 p.m. ET.
Investors, analysts, media and the public may listen to a live audio webcast of the presentation via the company's provided weblink.
Merck (NYSE: MRK) announced that Chirfi Guindo, chief marketing officer, Human Health, and Dr. Eliav Barr, senior vice president, head of global clinical development and chief medical officer, Merck Research Laboratories, will participate in a fireside chat at the 8th Annual Evercore ISI HealthCONx Conference on Tuesday, Dec. 2, 2025 at 9:10 a.m. ET.
Investors, analysts, media and the public are invited to listen via a live audio webcast accessible through the company’s investor relations webcast page.
Merck (NYSE: MRK) will present new hematology data at the American Society of Hematology (ASH) Annual Meeting, Dec. 6-9, 2025, in Orlando.
More than 20 abstracts cover multiple malignancies and investigational programs including MK-1045 (CD19xCD3 T-cell engager), bomedemstat (LSD1 inhibitor) and nemtabrutinib (non-covalent BTK inhibitor), plus updated results for zilovertamab vedotin (ROR1 ADC).
Highlights include first presentations of updated Phase 1b/2 MK-1045 results (Abstract #647), first-time Phase 2 bomedemstat Shorespan-004 data in polycythemia vera (Abstract #83), and exploratory nemtabrutinib genomic analyses from BELLWAVE-003 (Abstract #797).
Merck (NYSE: MRK) said it was notified of an unsolicited mini-tender from Tutanota dated November 10, 2025, to buy up to 1,000,000 shares at $65.00 per share.
The company noted the offer price is about 24.66% below the Nov 7, 2025 close ($86.28) and about 31.56% below the Nov 20, 2025 close ($94.97), and recommended shareholders reject and not tender their shares. Merck warned the offer is subject to conditions including Tutanota obtaining financing, is not associated with Merck, and cited SEC guidance that mini-tenders may sell shares below market prices. The offer currently expires at 5:00 p.m. EST on December 15, 2025.
Merck (NYSE: MRK) announced FDA approvals on November 21, 2025 for KEYTRUDA (pembrolizumab) and KEYTRUDA QLEX (pembrolizumab + berahyaluronidase alfa) each in combination with Padcev (enfortumab vedotin) as perioperative therapy for adults with cisplatin-ineligible muscle-invasive bladder cancer (MIBC).
Approvals follow Phase 3 KEYNOTE-905 (EV-303): EFS HR=0.40 (60% reduction), OS HR=0.50 (50% improvement), and a pCR rate 57.1% vs 8.6%. The regimens are the first PD-1 inhibitor plus ADC options for this patient group.
Merck (NYSE: MRK) reported topline Phase 3 results for the investigational once-daily oral two-drug single-tablet doravirine/islatravir (DOR/ISL 100 mg/0.25 mg) in treatment-naïve adults with HIV-1.
The trial met its primary efficacy endpoint at Week 48, showing non-inferiority on the proportion with HIV-1 RNA <50 copies/mL versus bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF), and met the primary safety objective with a comparable safety profile. Merck plans detailed data presentation at a scientific congress and regulatory submissions.
The FDA accepted an NDA for DOR/ISL for use to replace current regimens in virologically suppressed adults and set a PDUFA target action date of April 28, 2026.
Merck (NYSE: MRK) announced that the European Commission approved KEYTRUDA SC (pembrolizumab with berahyaluronidase alfa) for all adult KEYTRUDA indications across the EU, Iceland, Liechtenstein and Norway on November 19, 2025.
The approval makes KEYTRUDA the first and only subcutaneous immune checkpoint inhibitor in Europe, with administration in as little as 1 minute every 3 weeks or 2 minutes every 6 weeks. Approval was supported by the pivotal 3475A-D77 trial showing comparable pharmacokinetic exposure and similar overall response rates (KEYTRUDA SC+chemo ORR 45% [95% CI 39–52] vs KEYTRUDA+chemo ORR 42% [95% CI 33–51]). Commercial rollout timing will depend on national reimbursement processes.
Merck (NYSE: MRK) declared a quarterly dividend of $0.85 per share for the first quarter of 2026. Payment is scheduled for Jan. 8, 2026 to shareholders of record at the close of business on Dec. 15, 2025.
Merck (NYSE: MRK) reported positive topline results from the Phase 2 CADENCE study of WINREVAIR (sotatercept-csrk) in adults with combined post- and precapillary pulmonary hypertension (CpcPH) due to heart failure with preserved ejection fraction (HFpEF).
CADENCE met its primary endpoint, showing a statistically significant and clinically meaningful reduction in pulmonary vascular resistance (PVR) from baseline at 24 weeks versus placebo. A preliminary safety assessment was generally consistent with the known WINREVAIR safety profile. The company intends to proceed with Phase 3 development and plans to present detailed results at a future scientific congress. WINREVAIR is FDA approved for pulmonary arterial hypertension and is approved in >50 countries.
FAQ
What is the current stock price of Merck & Co (MRK)?
What is the market cap of Merck & Co (MRK)?
